CRC Research Update — July 06, 2026
Today's colorectal cancer research highlights
braf
A collection of 56 issues
BREAKWATER explores molecular markers in BRAF V600E disease
Skip to content
The CRC Digest
BREAKWATER explores molecular markers in BRAF V600E disease
Phase III trial data from ESMO GI examines correlates of response to encorafenib plus cetuximab and chemo. (Oncodaily)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care team.
CRC Research Update — June 25, 2026
Today's colorectal cancer research highlights
CRC Research Update — June 10, 2026
Today's colorectal cancer research highlights
BRAF V600E screening identifies candidates for perioperative therapy
Skip to content
The CRC Digest
BRAF V600E screening identifies candidates for perioperative therapy
Multicenter screening evaluated preoperative BRAF V600E mutation detection in patients with resectable colorectal oligometastases, enabling recruitment to a trial of the BEACON triplet regimen. (Int J Clin Oncol)
This content is informational only and does not
CRC Research Update — June 06, 2026
Today's colorectal cancer research highlights
CRC Research Update — June 04, 2026
Today's colorectal cancer research highlights
CRC Research Update — June 01, 2026
Today's colorectal cancer research highlights
BRAF V600E triplet regimen advances in phase 3 trial
Skip to content
The CRC Digest
BRAF V600E triplet regimen advances in phase 3 trial
BREAKWATER Cohort 3 evaluated encorafenib + cetuximab + FOLFIRI versus FOLFIRI ± bevacizumab in previously untreated BRAF V600E-mutant mCRC, with primary endpoint of objective response rate and key secondary endpoint of progression-free survival. (Annals of Oncology)
This content
This Week in CRC Research — May 31, 2026
Weekly colorectal cancer research intelligence